Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient | Zendy

María F. Mojica | Zendy; Christopher P. Ouellette | Zendy; Amy L. Leber | Zendy; M. Brian Becknell | Zendy; Monica I. Ardura | Zendy; Federico Pérez | Zendy; Masako Shimamura | Zendy; Robert A. Bonomo | Zendy; Samuel L Aitken | Zendy; Samuel A. Shelburne | Zendy

Open Access

Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient

Author(s) -

María F. Mojica,

Christopher P. Ouellette,

Amy L. Leber,

M. Brian Becknell,

Monica I. Ardura,

Federico Pérez,

Masako Shimamura,

Robert A. Bonomo,

Samuel L Aitken,

Samuel A. Shelburne

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00264-16

Subject(s) - stenotrophomonas maltophilia , colistin , bacteremia , medicine , antibiotics , microbiology and biotechnology , drug resistance , multiple drug resistance , renal transplant , refractory (planetary science) , pathogen , intensive care medicine , pseudomonas aeruginosa , transplantation , biology , immunology , bacteria , genetics , astrobiology

Stenotrophomonas maltophilia is an emerging multidrug-resistant (MDR) opportunistic pathogen for which new antibiotic options are urgently needed. We report our clinical experience treating a 19-year-old renal transplant recipient who developed prolonged bacteremia due to metallo-β-lactamase-producingS. maltophilia refractory to conventional treatment. The infection recurred despite a prolonged course of colistimethate sodium (colistin) but resolved with the use of a novel drug combination with clinical efficacy against the patient'sS. maltophilia isolate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research